Biotechnology stocks have soared this past year - the iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) returned an impressive 34% in 2014 - so it's not surprising that companies are stepping up their biotech offerings in order to take advantage of current demand. One of those offerings that hit the market in just the last week is attempting to differentiate itself by targeting a very unique niche of the market.
The BioShares Biotechnology Clinical Trials ETF (NASDAQ:BBC) invests in biotech firms with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development. According to the fund's fact sheet:
Click the button below to read the rest of this original article on Seeking Alpha.
ETF Research
We cover ETFs across all sectors, regions and markets. We analyze the portfolios themselves as well as the macro environments that affect them.
Mutual Fund Research
We do mutual fund research too! Although not covered quite as in-depth as the ETF world, we've still profiled many of the big names!
Investing Strategy
Everything from retirement planning to 401(k) investing to options trading strategies and everything in between!
Next Steps...
Got a question? A comment? A fund you want to see profiled? Let us know!
